

# Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)

Technology appraisal guidance

Published: 28 March 2024

[www.nice.org.uk/guidance/ta961](https://www.nice.org.uk/guidance/ta961)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of sebelipase alfa for treating lysosomal lipase deficiency that is not Wolman disease. The Wolman disease population was evaluated separately in [NICE highly specialised technology guidance on sebelipase alfa](#) (HST30). The cost effectiveness of the remaining non-Wolman population has not been demonstrated at this stage.

## Information

If NHS organisations wish to consider sebelipase alfa for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review this decision if the company makes a submission in the remaining non-Wolman population.

ISBN: 978-1-4731-5882-5

## Accreditation

